IGC Pharma (FRA:IGS1) Net Change in Cash : €-0.86 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

IGC Pharma's Net Change in Cash for the three months ended in Dec. 2024 was €-1.03 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.86 Mil.

IGC Pharma Net Change in Cash Historical Data

The historical data trend for IGC Pharma's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Net Change in Cash Chart

IGC Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Change in Cash

Get a 7-Day Free Trial

-16.61

6.12

-3.71

-6.79

-1.84

IGC Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Change in Cash	Get a 7-Day Free Trial															-1.51	-0.17	0.58	-0.25	-1.03

IGC Pharma Net Change in Cash Calculation

IGC Pharma's Net Change in Cash for the fiscal year that ended in Mar. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-4.783	+	-0.292	+	3.242	+	-0.006
	=	-1.84

IGC Pharma's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -1.258 + -0.099 + 0.329 + 0

= -1.03

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma Net Change in Cash Related Terms
Thank you for viewing the detailed overview of IGC Pharma's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Net Change in Cash

Comparable Companies

BCAB NNVC LGVN TENX CGTX IBO CARA LEXX LVTX ENLV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Headlines

No Headlines